Navigation Links
Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Date:9/2/2008

ere 1.406 and 1.199L for ACCLAIM/COPD I and ACCLAIM/COPD II, respectively. Patients were randomized to receive aclidinium bromide (200 micrograms once daily) or placebo over a one-year treatment period.

The primary endpoints for ACCLAIM/COPD I and II were bronchodilation at the end of the dosing interval, assessed as trough FEV1 (measured at 23-24h post-dose). For both trials, the primary endpoint was measured at week 12 and week 28 to fulfill FDA and European requirements, respectively.

Aclidinium bromide and placebo were administered to patients using the Genuair(R)(1) device, a multi-dose dry powder inhaler which operates by a 'one press and inhale' technique.

Overall, safety and tolerability were comparable between aclidinium and placebo in terms of percentage of patients with Serious Adverse Events (aclidinium: 9.1%, placebo 10.7%), Fatal Adverse Events (aclidinium: 1.1%, placebo: 1.7%), or with Adverse Events leading to treatment discontinuation (aclidinium: 4.0%, placebo: 5.7%). The most frequently reported adverse events across both studies were nasopharyngitis (aclidinium: 14.5%, placebo: 12.9%) and headache (aclidinium: 12.7%, placebo: 12.6%). Potential anticholinergic adverse events were observed in a similarly low percentage of patients, (e.g. dry mouth - aclidinium: 0.7%, placebo: 1.2%).

"Almirall remains committed to continue the efforts to provide treatment options for COPD patients with aclidinium bromide", commented Jorge Gallardo, Chairman and Chief Executive Officer of Almirall.

About COPD

The World Health Organisation (WHO) has described COPD as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.

The most
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will attend The Benchmark Company, LLC,s Micro Cap ... will be held at The Palmer House Hilton, 17 E. ... a.m. to 2:30 p.m. Please email hska@haydenir.com or ...
(Date:11/26/2014)... BOCA RATON, Fla. , Nov. 25, 2014 ... has entered into a multi-product ANDA agreement with ... Maryland ) under which Breckenridge and Pii ...  Under the terms of the agreement, Pii will ... will market and distribute the products under its ...
(Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... or "the Company"), a clinical stage biopharmaceutical company ... targeted therapeutics for the treatment of inflammatory diseases ... previously announced underwritten public offering of 3,450,000 units, ... the Company,s common stock, par value $0.0001 per ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) ... 31, 2011. "We are pleased to have completed ... the FDA this year to reach agreement on the protocol ... treatment of sickle cell crisis," said Brian M. Culley, Chief ...
... CYPRESS, Calif., May 9, 2011 Medison and Samsung ... Medison. The combined company, a joint partnership between Korea,s ... world,s largest and most technologically-advanced electronics and consumer goods ... into a global leader in medical device industry. ...
Cached Medicine Technology:ADVENTRX Reports First Quarter 2011 Financial Results 2ADVENTRX Reports First Quarter 2011 Financial Results 3ADVENTRX Reports First Quarter 2011 Financial Results 4ADVENTRX Reports First Quarter 2011 Financial Results 5Samsung Medison Pledges to Become a World-Class Medical Device Company 2
(Date:11/27/2014)... Luciana Lagana and her husband ... Omadox, a feature film that received 9 awards at the ... ensemble cast. It is also an official selection of the ... a successful cinematic career for James Noel, a young filmmaker ... enjoy experimental mystery, filmed in glorious black and white, watching ...
(Date:11/27/2014)... 27, 2014 Blood-borne pathogens raise the ... precautions and procedures in place to counter this. However, ... of things tainted with menstrual blood are taken as ... simpler, more sanitary way to handle tampons and menstrual ... from Sonora, Calif. , He then created a prototype ...
(Date:11/27/2014)... 27, 2014 Nearly 1,100 Risperdal ... in a consolidated litigation now underway in Pennsylvania ... Documents recently updated in the Philadelphia Court of ... state proceeding, all of which involve a drug ... psychiatric conditions. Many of the cases in this ...
(Date:11/27/2014)... By Dennis Thompson ... -- An experimental Ebola vaccine appears to be safe and ... the deadly virus, according to early clinical trial results reported ... of the phase I clinical trial for the vaccine paves ... nations of Liberia and Sierra Leone as early as January, ...
(Date:11/27/2014)... The founders of VIM & VIGR, a ... functioning compression socks, are proud to announce the debut of ... Gradient Pressure (TM) knitting technology that is designed to increase ... commitment to adding flair and style to a product that ... the eye of a writer at The New York ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
... Sciences Corporation announced,today a new initiative that ... instruments used in medical practice and healthcare,2.0 ... draws upon the,cognitive and anthropologic sciences, is ... human intelligence,s reliance on,narrative for richly conveying ...
... Build Healthy Communities, VICTORVILLE, Calif., April 16 ... Victorville Earth Day Eco Tote giveaway.,On Tuesday, April ... will be handing out recyclable Eco Totes to ... Reduce, Reuse, Recycle program, Heritage Victor Valley,Medical Group ...
... have discovered sleep patterns in a type of anesthesia ... snooze. , The anesthetic used in the study, known ... tool to more thoroughly investigate ways of treating sleep ... one of the studys co-authors and an associate professor ...
... AFL ) announced today that it will ... on April 23, 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20041202/CLTH019LOGO ... release, Aflac Incorporated will,webcast a conference call scheduled ... the teleconference, Aflac Incorporated Chairman and CEO Dan ...
... middle could be making us hungrier, so we eat more, ... Dr. Yaiping Yang and his colleagues at the Lawson Health ... abdominal fat tissue can reproduce a hormone that stimulates fat ... in the way we think about and treat abdominal obesity. ...
... Management Program improves patient care while ... saving ... of its inaugural Best Practices in Consumer Empowerment and,Protection Awards ... NeuroScience, Inc. and Eli Lilly,and Company as Silver Award winners ...
Cached Medicine News:Health News:IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments 2Health News:IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments 3Health News:Aflac Incorporated To Release First Quarter Results on April 23, 2008 2Health News:Your belly fat could be making you hungrier 2Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 2Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 3Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 4